[Molecular Genetic Testing for Acute Myeloid Leukemia].

Area of Science:

• Hematology
• Molecular Oncology
• Genetics

Background:

• Acute myeloid leukemia (AML) is a complex disease with significant molecular heterogeneity.
• Conventional cytogenetics are insufficient for prognostication in up to half of AML patients with normal karyotypes.
• Next-generation sequencing has identified recurrent mutations improving prognosis and treatment strategies in cytogenetically normal AML.

Purpose of the Study:

• To review significant mutations in cytogenetically normal AML.
• To discuss the prognostic implications of these mutations.
• To highlight their role in minimal residual disease monitoring and targeted therapy development.

Main Methods:

• Review of current literature on molecular mutations in AML.
• Analysis of prognostic significance of identified mutations.
• Evaluation of mutations for minimal residual disease monitoring and therapeutic targeting.

Main Results:

• Specific gene mutations significantly enhance prognostic accuracy in cytogenetically normal AML.
• These mutations serve as valuable biomarkers for minimal residual disease detection.
• Identified mutations represent potential targets for novel therapeutic agents.

Conclusions:

• Molecular genetic testing is essential for comprehensive AML diagnosis and risk stratification.
• Understanding mutation profiles aids in personalized treatment approaches and monitoring treatment response.
• Gene mutation accumulation influences clonal evolution and AML relapse dynamics.